SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(te Marvelde Luc)
 

Sökning: WFRF:(te Marvelde Luc) > (2018) > Tumor PIK3CA Genoty...

  • Zardavas, DimitriosBreast Int Grp, Belgium,Breast International Group (författare)

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data

  • Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

  • AMER SOC CLINICAL ONCOLOGY,2018
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-148658
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-148658URI
  • https://doi.org/10.1200/JCO.2017.74.8301DOI
  • https://lup.lub.lu.se/record/1b5cd624-1b72-4b9b-aa8f-0e105942a187URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|Cancer Council Victoria; National Health and Medical Research Council of Australia; National Breast Cancer Foundation, Australia; Breast Cancer Research Foundation, New York; Fonds de la Recherche Scientifique; Ontario Institute for Cancer Research; Government of Ontario; Trentino Biomolecular Oncologic Network (Trebionet) project; Swedish Research Council; Swedish Cancer Society
  • PurposePhosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations are frequently observed in primary breast cancer. We evaluated their prognostic relevance by performing a pooled analysis of individual patient data.Patients and MethodsAssociations between PIK3CA status and clinicopathologic characteristics were tested by applying Cox regression models adjusted for age, tumor size, nodes, grade, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, treatment, and study. Invasive disease-free survival (IDFS) was the primary end point; distant disease-free survival (DDFS) and overall survival (OS) were also assessed, overall and by breast cancer subtypes.ResultsData from 10,319 patients from 19 studies were included (median OS follow-up, 6.9 years); 1,787 patients (17%) received chemotherapy, 4,036 (39%) received endocrine monotherapy, 3,583 (35%) received both, and 913 (9%) received none or their treatment was unknown. PIK3CA mutations occurred in 32% of patients, with significant associations with ER positivity, increasing age, lower grade, and smaller size (all P amp;lt; .001). Prevalence of PIK3CA mutations was 18%, 22%, and 37% in the ER-negative/HER2-negative, HER2-positive, and ER-positive/HER2-negative subtypes, respectively. In univariable analysis, PIK3CA mutations were associated with better IDFS (HR, 0.77; 95% CI, 0.71 to 0.84; P amp;lt; .001), with evidence for a stronger effect in the first years of follow-up (0 to 5 years: HR, 0.73; 95% CI, 0.66 to 0.81; P amp;lt; .001; 5 to 10 years: HR, 0.82; 95% CI, 0.68 to 0.99; P = .037); amp;gt; 10 years: (HR, 1.15; 95% CI, 0.84 to 1.58; P = .38; P heterogeneity = .02). In multivariable analysis, PIK3CA genotype remained significant for improved IDFS (P = .043), but not for the DDFS and OS end points.ConclusionIn this large pooled analysis, PIK3CA mutations were significantly associated with a better IDFS, DDFS, and OS, but had a lesser prognostic effect after adjustment for other prognostic factors. (C) 2018 by American Society of Clinical Oncology

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • te Marvelde, LucCanc Council, Australia (författare)
  • Milne, Roger L.Canc Council, Australia; Univ Melbourne, Australia,University of Melbourne (författare)
  • Fumagalli, DeboraBreast Int Grp, Belgium,Breast International Group (författare)
  • Fountzilas, GeorgeAristotle Univ Thessaloniki, Greece,Aristotle University of Thessaloniki (författare)
  • Kotoula, VassilikiAristotle Univ Thessaloniki, Greece,Aristotle University of Thessaloniki (författare)
  • Razis, EvangeliaHygeia Hosp, Greece,Hygeia Hospital (författare)
  • Papaxoinis, GeorgeHippokrateion Hosp, Greece,Hippokration Hospital (författare)
  • Joensuu, HeikkiHelsinki Univ Hosp, Finland; Univ Helsinki, Finland,University of Helsinki,Helsinki University Central Hospital,Leiden University Medical Centre,Leiden Univ, Netherlands (författare)
  • Moynahan, Mary EllenMem Sloan Kettering Canc Ctr, NY 10021 USA,Memorial Sloan-Kettering Cancer Center (författare)
  • Hennessy, Bryan T.Beaumont Hosp, Ireland; Royal Coll Surg, Ireland,Beaumont Hospital, Dublin (författare)
  • Bieche, IvanCurie Inst, France,Curie Institute, Paris (författare)
  • Saal, Lao H.Lund University,Lunds universitet,Translational Oncogenomics,Forskargrupper vid Lunds universitet,Lund University Research Groups,Lund Univ, Sweden(Swepub:lu)onk-ls0 (författare)
  • Stål, OlleLinköping University,Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US(Swepub:liu)ollst87 (författare)
  • Iacopetta, BarryUniv Western Australia, Australia,University of Western Australia, Crawley (författare)
  • Jensen, Jeanette DupontUniv Southern Denmark, Denmark,University of Southern Denmark (författare)
  • OToole, SandraGarvan Inst Med Res, Australia,Garvan Institute of Medical Research (författare)
  • Lopez-Knowles, ElenaGarvan Inst Med Res, Australia; Royal Marsden NHS Trust, England; Inst Canc Res, England,Garvan Institute of Medical Research,Institute of Cancer Research London (författare)
  • Barbaraeschi, MattiaSanta Chiara Hosp, Italy,Santa Chiara Hospital, Trento (författare)
  • Noguchi, ShinzaburoOsaka Univ, Japan,Osaka University (författare)
  • Azim, Hatem A. Jr.Amer Univ Beirut, Lebanon,American University of Beirut (författare)
  • Lerma, EnriqueUniv Autonoma Barcelona, Spain,Autonomous University of Barcelona (författare)
  • Bachelot, ThomasCtr Rech Cancerol Lyon, France,Centre de Recherche en Cancérologie de Lyon (författare)
  • Wang, QingLinköping University,Linköpings universitet (författare)
  • Perez Tenorio, GizehLinköping University,Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten(Swepub:liu)gizpe86 (författare)
  • de Velde, Cornelis J. H. CanLeiden Univ, Netherlands (författare)
  • Rea, Daniel W.Univ Birmingham, England,University of Birmingham (författare)
  • Sabine, VickyUniv Guelph, Canada,University of Guelph (författare)
  • Bartlett, John M. S.Ontario Inst Canc Res, Canada,Ontario Institute for Cancer Research,University of Paris-Saclay,Gustave Roussy, France; Univ Paris Saclay, France (författare)
  • Sotiriou, ChristosUniv Libre Bruxelles, Belgium,Université Libre de Bruxelles (ULB) (författare)
  • Michiels, StefanGustave Roussy, France; Univ Paris Saclay, France (författare)
  • Loi, ShereneUniv Melbourne, Australia,University of Melbourne (författare)
  • Breast Int Grp, BelgiumBreast International Group (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Clinical Oncology: AMER SOC CLINICAL ONCOLOGY36:10, s. 981-+0732-183X1527-7755

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy